A Descriptive Evaluation of Prescriber Perceptions and Experience With Risk Evaluation and Mitigation Strategy (REMS) Programs in an Integrated Health Care System.

Objective: To assess prescriber perceptions and experience with risk evaluation and mitigation strategy (REMS) programs in an integrated health care delivery system.

Methods: A cross-sectional online survey was e-mailed to eligible health care prescribers if they prescribed at least 1 selected REMS-related product within 6 months spanning January 1 to June 30, 2013; were an active employee of Kaiser Permanente Southern California; and had an active " kp.org " e-mail address.

Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series.

Ipilimumab is a fully human, monoclonal antibody directed against Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) that has demonstrated a survival benefit and durable disease control in patients with advanced melanoma. Ipilimumab is associated with potentially serious immune-related adverse events, including autoimmune hepatitis. Because clinical trials of ipilimumab excluded patients with pre-existing hepatitis B or C infection, there is a paucity of data on the safety of ipilimumab administration to that patient population.